DUBLIN, January 5, 2023 /PRNewswire/ — The report “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials and Trends, 2023” has been added to researchandmarkets.com offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy in which doctors collect immune cells, modify them in a laboratory, and give them the power to easily recognize and kill cancer cells. When infused into a patient, the cells multiply and remain in the body as “living drugs.”
T cells form the backbone of CAR-T cell therapy. T cells are the workhorses of our immune system and play a key role in directing the immune response and destroying cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T cells are separated. In the laboratory, a disarmed virus is used to genetically engineer T cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs allow T cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.
Scientific progress in the field of cancer immunotherapy has led to seven CAR-T cell therapy approvals, including:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagen ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lysocabtagen maraleucel)
- Abecma (idecabtagene vicleucel)
- Relma-cel (Relmacabtagen)
- Carvykti (Ciltacabtagene autoleucel)
Although Relma-cel has been approved by NMPA in Porcelainthe other six therapies have been approved in the US by the FDA.
These landmark approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. This has taken CAR-T funding to amazing new heights. At first, the trend was subtle, but the tide has risen as new CAR-Ts have been heavily funded by investors keen to break into this expanding area of regenerative medicine. Altogether, there has been an astonishing $100 billion market capitalization of CAR-T companies in recent years.
Financing rounds for CAR-T companies are approaching $4 billionwhile CAR-T industry associations have contributed an astonishing $2 billion. M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics over $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene to $74 billion by 2019. Gilead’s acquisition of Kite Pharma by $11.9 billion also made waves, as did other transactions, such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology to $665 million. The multi-billion dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of early CAR-T therapies in treating various types of blood cancers. From small start-ups to multi-billion dollar companies, CAR-T companies are proliferating in all healthcare markets around the world.
This 321-page market report reveals:
- Size of the global CAR-T cell therapy market, with segmentation by product, geography, and indication
- Future forecasts of the market size by segment until 2030
- Detailed coverage of approved CAR-T products, including regulatory approvals, pricing, reimbursement, and degree of market penetration
- Clinical Trial Activity by Type, Geography, Phase, and Sponsor
- Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and most cited patents
- CAR-T Industry M&A, Initial Public Offerings, and Financing Events
- Strategic associations, alliances and co-marketing agreements within the CAR-T sector
- Market trends, future directions and emerging opportunities
- Profiles of the main CAR-T competitors that make up the global market
- and much more.
Key topics covered:
1. SUMMARY OF THE REPORT
2. THERAPY WITH CAR-T CELLS: TECHNOLOGY DEVELOPMENT
2.1 CAR-T cell
2.2 Evolution of CAR-T cell development
2.3 Antigens present on hematological malignant cells
2.4 Tools for inserting receptor genes into T cells
2.5 Transformation of T cells into CAR-T cells
2.6 The seven commercially available CAR-T therapies: a brief overview
2.7 Toxicities Associated with CAR-T Treatment
2.8 Strategies for the future of CAR-T therapies
2.8.1 Switchable CARs (sCAR)
2.8.2 Suicide genes to kill CAR-T cells in vivo
2.8.3 Transient transfection
2.8.4 Affinity-tuned CARs
2.8.5 Armored cars
2.8.6 Change from liquid cancers to solid tumors
2.8.7 Focus on shortening hospital stay
2.8.8 Focus on discovering new antigens
2.8.9 Switching from autologous to allogeneic CAR-T therapies
2.8.10 CAR-T for the masses
2.8.11 New approach CAR-T In Vivo
2.8.12 Combination with mRNA vaccine
2.8.13 Combination with Oncolytic Virus
2.9 Direct competition between autologous CAR-T therapies
3. THERAPY WITH CAR-T CELLS: PRODUCT DEVELOPMENT
4. SCALABLE MANUFACTURING OF CAR-T CELLS
4.1 The manufacturing process for autologous CAR-T therapies on a clinical scale
4.2 The evolution of CAR-T cell manufacturing platforms
4.2.1 Open systems vs. closed
4.2.2 Manual processing versus automation
4.2.3 Autologous vs. Allogeneic Manufacturing
4.4 Operating Expenses in the Autologous Manufacture of CAR-T
4.5 Operating Expenses in CAR-T Allogeneic Manufacturing
5. CAR-T TARGET ANTIGENS
6. OVERVIEW OF CAR-T PATENTS
7. OVERVIEW OF THE CAR-T CLINICAL TRIAL
8. CAR-T SCIENTIFIC PAPERS PUBLISHED WITH FUNDING FROM PUBMED.GOV AND NIH
9. OFFERS IN THE CAR-T THERAPY SPACE
9.1 Latest CAR-T offers
10. REIMBURSEMENT FOR CAR-T THERAPIES
10.1 Potential barriers to CAR-T treatments
10.2 Manufacturer challenges
10.3 Updated CAR-T Reimbursement for FY2023 IPPS Final Rule
10.4 Use of 2021 data to establish payment
10.5 Reimbursement for CAR-T Therapy in Europe
10.6 Outcome-Based Reimbursement for CAR-T Therapies in Europe
10.7 Patients treated with CAR-T cells registered in the EBMT registry
11. BLOOD CANCER: INCIDENCE AND AVAILABLE TREATMENTS
11.1 Lymphoma
11.2 Leukemia
11.3 Treatment options for blood cancers
11.4 The staggering cost of cancer therapies
12. MARKET ANALYSIS
12.1 Global CAR-T Cell Therapy Market by Product
12.2 Global Market for CAR-T Therapy by Geography
12.3 Global CAR-T Therapy Market by Indication
13. BARRIERS AND STRATEGIES FOR SUCCESS IN THE CAR-T 2.0 MARKET
13.1 Barriers to the commercial success of CAR-T 2.0
13.2 Capacity Restrictions
13.3 Competition between manufacturers
13.4 Competition of other Treatments
13.5 Market Development Strategies for CAR-T 2.0
13.5.1 Effective medical education
13.5.2 Logistics excellence
13.5.3 Generation of evidence
14. CAR-T COMPANIES: AN OVERVIEW
Mentioned companies
- abbvie
- Adaptimmune
- Fin BioTherapeutics
- halogenic
- Allogeneic therapeutics
- Anixa Biosciences, Inc.
- Applied DNA Sciences, Inc.
- arcellx, inc.
- Astellas Pharma
- Atara Biotherapeutics
- Autolus Therapeutics, plc
- Bellicum Pharmaceuticals, Inc.
- BioNTech
- blue bird biography
- Bristol board-myers squibb (BMS)
- Cabaletta Biography
- Caribou Biosciences
- Carina Biotechnology
- Charisma Therapeutics, Inc.
- CARsgen Therapeutics
- Cartesian Therapeutics, Inc.
- CARTherics
- Celgene Corporation
- Cell Therapies, Pvt. Limited
- cellectis
- Cellularity, Inc.
- celiac oncology
- Creative Biological Laboratories
- CRISPR therapeutics
- CytoSeek
- cytovia therapeutics
- DiaCarta, Inc.
- Dr. Reddy Laboratories
- Empirical Therapeutics
- More
For more information on this report, please visit https://www.researchandmarkets.com/r/scyczp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.
Media Contact:
Research and Markets
laura woodSenior manager
[email protected]
For EST business hours call +1-917-300-0470
For USA/Canada call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
